

## PATIENT INFORMATION

PATIENT NAME: \_\_\_\_\_ PHONE: \_\_\_\_\_

DATE OF BIRTH: \_\_\_\_\_ SEX: ☐ M ☐ F HEIGHT: \_\_\_\_\_ WEIGHT: \_\_\_\_\_ ☐ LBS ☐ KG

ALLERGIES: \_\_\_\_\_ PREFERRED CLINIC: \_\_\_\_\_

REFERRAL STATUS: ☐ NEW REFERRAL ☐ ORDER CHANGE ☐ ORDER RENEWAL

## DIAGNOSIS & CLINICAL DOCUMENTATION

☐ G61.81 Chronic inflammatory demyelinating polyneuritis (CIDP)

☐ G70.00 Myasthenia gravis w/o acute exacerbation (gMG)

☐ G70.01 Myasthenia gravis with acute exacerbation (gMG)

☐ ICD-10 CODE: \_\_\_\_\_ DESCRIPTION: \_\_\_\_\_

## REQUIRED DOCUMENTATION

☐ Insurance Information

☐ List of Medications

☐ Tried & Failed Therapies

☐ Most Recent History & Physical

☐ MG-ADL Score / MGFA classification

☐ Positive AChR Antibody (gMG)

## MEDICATION ORDER

### FOR CIDP

☐ Vyvgart Hytrulo® (efgartigimod alfa & hyaluronidase) 1,008 mg/11,200 units subcutaneously over 30 to 90 seconds once weekly

☒ REFILL X 12 MONTHS UNLESS OTHERWISE NOTED HERE: \_\_\_\_\_

### FOR gMG

☐ **CYCLE:** Vyvgart Hytrulo® (efgartigimod alfa & hyaluronidase) 1,008 mg/11,200 units subcutaneously over 30 to 90 seconds once weekly for 4 weeks

☐ Repeat cycle \_\_\_\_\_ week(S) from date of last infusion; patient to receive a total of \_\_\_\_\_ cycles

Patient to be observed for 30 minutes following each infusion.

In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.

## PRESCRIBER INFORMATION

PROVIDER NAME: \_\_\_\_\_ NPI #: \_\_\_\_\_

EMAIL: \_\_\_\_\_ PHONE: \_\_\_\_\_ FAX: \_\_\_\_\_

ADDRESS (INCLUDE CITY, STATE, ZIP): \_\_\_\_\_

SUPERVISING PHYSICIAN: \_\_\_\_\_ CONTACT NAME: \_\_\_\_\_  
(IF APPLICABLE)

SIGNATURE: \_\_\_\_\_ DATE: \_\_\_\_\_  
(NO STAMPS)

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN